Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)

Alejandro Recio-Boiles, Jose N. Galeas, Bernard Goldwasser, Karla Sanchez, Louise M.W. Man, Ryan D. Gentzler, Jane Gildersleeve, Patricia J. Hollen, Richard J. Gralla

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Purpose: Ongoing cancer cachexia trials evaluate sarcopenia by skeletal muscle index (SMI) at the L3 vertebrae level, commonly used as a standard. Routine chest CT institutional protocols widely differ in including L3. We investigated whether SMI at L1 assessment, rather than L3, would be reliable and more practicable for non-small cell lung cancer (NSCLC). Methods: NSCLC patients with routine CT chest had SMI measurements performed at L1 using Slice-O-Matic software. Accuracy of including L1 level, imaging quality, and ability to detect sarcopenia was collected and correlation of L1 SMI with body mass index (BMI) was performed. Results: Thirty-seven patients with NSCLC (73 CT assessments) were enlisted at three institutions. Characteristics: 47% female; medians: age 59, KPS 80%; BMI 25.49, weight 72.97 kg, SMI 59.24. Sarcopenia was detected in 14.7% of patients; 20% had sarcopenic obesity. Of the 73 CTs, 94.5% included L1 (95% CI 86.6–98.5%). Three images (4%) were difficult to evaluate. Inclusion of L1 was similar among the three participating institutions (90.4 to 96.7% inclusion). BMI correlation with SMI was weak (r = 0.329). Conclusions: SMI assessment at L1 is achievable in patients with NSCLC receiving routine chest CT, with 96% having acceptable quality evaluations. Similar to results previously reported at L3, BMI showed poor correlation and low sensitivity to detect muscle mass loss. The use of CT at L1 is reliable and presents the opportunity for easier patient evaluation of sarcopenia in patients with lung cancer without the need for additional testing or radiation exposure.

Original languageEnglish (US)
Pages (from-to)1-7
Number of pages7
JournalSupportive Care in Cancer
DOIs
StateAccepted/In press - Feb 7 2018

Fingerprint

Sarcopenia
Non-Small Cell Lung Carcinoma
Skeletal Muscle
Thorax
Tomography
Body Mass Index
Cachexia
Lung Neoplasms
Spine
Software
Obesity
Weights and Measures
Muscles

Keywords

  • Cachexia
  • Chest CT
  • L1
  • Lung cancer
  • Sarcopenia
  • Skeletal muscle mass

ASJC Scopus subject areas

  • Oncology

Cite this

Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT). / Recio-Boiles, Alejandro; Galeas, Jose N.; Goldwasser, Bernard; Sanchez, Karla; Man, Louise M.W.; Gentzler, Ryan D.; Gildersleeve, Jane; Hollen, Patricia J.; Gralla, Richard J.

In: Supportive Care in Cancer, 07.02.2018, p. 1-7.

Research output: Contribution to journalArticle

Recio-Boiles, Alejandro ; Galeas, Jose N. ; Goldwasser, Bernard ; Sanchez, Karla ; Man, Louise M.W. ; Gentzler, Ryan D. ; Gildersleeve, Jane ; Hollen, Patricia J. ; Gralla, Richard J. / Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT). In: Supportive Care in Cancer. 2018 ; pp. 1-7.
@article{18c4ab3f63f845b59f00f3ea7dbd739e,
title = "Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)",
abstract = "Purpose: Ongoing cancer cachexia trials evaluate sarcopenia by skeletal muscle index (SMI) at the L3 vertebrae level, commonly used as a standard. Routine chest CT institutional protocols widely differ in including L3. We investigated whether SMI at L1 assessment, rather than L3, would be reliable and more practicable for non-small cell lung cancer (NSCLC). Methods: NSCLC patients with routine CT chest had SMI measurements performed at L1 using Slice-O-Matic software. Accuracy of including L1 level, imaging quality, and ability to detect sarcopenia was collected and correlation of L1 SMI with body mass index (BMI) was performed. Results: Thirty-seven patients with NSCLC (73 CT assessments) were enlisted at three institutions. Characteristics: 47{\%} female; medians: age 59, KPS 80{\%}; BMI 25.49, weight 72.97 kg, SMI 59.24. Sarcopenia was detected in 14.7{\%} of patients; 20{\%} had sarcopenic obesity. Of the 73 CTs, 94.5{\%} included L1 (95{\%} CI 86.6–98.5{\%}). Three images (4{\%}) were difficult to evaluate. Inclusion of L1 was similar among the three participating institutions (90.4 to 96.7{\%} inclusion). BMI correlation with SMI was weak (r = 0.329). Conclusions: SMI assessment at L1 is achievable in patients with NSCLC receiving routine chest CT, with 96{\%} having acceptable quality evaluations. Similar to results previously reported at L3, BMI showed poor correlation and low sensitivity to detect muscle mass loss. The use of CT at L1 is reliable and presents the opportunity for easier patient evaluation of sarcopenia in patients with lung cancer without the need for additional testing or radiation exposure.",
keywords = "Cachexia, Chest CT, L1, Lung cancer, Sarcopenia, Skeletal muscle mass",
author = "Alejandro Recio-Boiles and Galeas, {Jose N.} and Bernard Goldwasser and Karla Sanchez and Man, {Louise M.W.} and Gentzler, {Ryan D.} and Jane Gildersleeve and Hollen, {Patricia J.} and Gralla, {Richard J.}",
year = "2018",
month = "2",
day = "7",
doi = "10.1007/s00520-018-4051-2",
language = "English (US)",
pages = "1--7",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Enhancing evaluation of sarcopenia in patients with non-small cell lung cancer (NSCLC) by assessing skeletal muscle index (SMI) at the first lumbar (L1) level on routine chest computed tomography (CT)

AU - Recio-Boiles, Alejandro

AU - Galeas, Jose N.

AU - Goldwasser, Bernard

AU - Sanchez, Karla

AU - Man, Louise M.W.

AU - Gentzler, Ryan D.

AU - Gildersleeve, Jane

AU - Hollen, Patricia J.

AU - Gralla, Richard J.

PY - 2018/2/7

Y1 - 2018/2/7

N2 - Purpose: Ongoing cancer cachexia trials evaluate sarcopenia by skeletal muscle index (SMI) at the L3 vertebrae level, commonly used as a standard. Routine chest CT institutional protocols widely differ in including L3. We investigated whether SMI at L1 assessment, rather than L3, would be reliable and more practicable for non-small cell lung cancer (NSCLC). Methods: NSCLC patients with routine CT chest had SMI measurements performed at L1 using Slice-O-Matic software. Accuracy of including L1 level, imaging quality, and ability to detect sarcopenia was collected and correlation of L1 SMI with body mass index (BMI) was performed. Results: Thirty-seven patients with NSCLC (73 CT assessments) were enlisted at three institutions. Characteristics: 47% female; medians: age 59, KPS 80%; BMI 25.49, weight 72.97 kg, SMI 59.24. Sarcopenia was detected in 14.7% of patients; 20% had sarcopenic obesity. Of the 73 CTs, 94.5% included L1 (95% CI 86.6–98.5%). Three images (4%) were difficult to evaluate. Inclusion of L1 was similar among the three participating institutions (90.4 to 96.7% inclusion). BMI correlation with SMI was weak (r = 0.329). Conclusions: SMI assessment at L1 is achievable in patients with NSCLC receiving routine chest CT, with 96% having acceptable quality evaluations. Similar to results previously reported at L3, BMI showed poor correlation and low sensitivity to detect muscle mass loss. The use of CT at L1 is reliable and presents the opportunity for easier patient evaluation of sarcopenia in patients with lung cancer without the need for additional testing or radiation exposure.

AB - Purpose: Ongoing cancer cachexia trials evaluate sarcopenia by skeletal muscle index (SMI) at the L3 vertebrae level, commonly used as a standard. Routine chest CT institutional protocols widely differ in including L3. We investigated whether SMI at L1 assessment, rather than L3, would be reliable and more practicable for non-small cell lung cancer (NSCLC). Methods: NSCLC patients with routine CT chest had SMI measurements performed at L1 using Slice-O-Matic software. Accuracy of including L1 level, imaging quality, and ability to detect sarcopenia was collected and correlation of L1 SMI with body mass index (BMI) was performed. Results: Thirty-seven patients with NSCLC (73 CT assessments) were enlisted at three institutions. Characteristics: 47% female; medians: age 59, KPS 80%; BMI 25.49, weight 72.97 kg, SMI 59.24. Sarcopenia was detected in 14.7% of patients; 20% had sarcopenic obesity. Of the 73 CTs, 94.5% included L1 (95% CI 86.6–98.5%). Three images (4%) were difficult to evaluate. Inclusion of L1 was similar among the three participating institutions (90.4 to 96.7% inclusion). BMI correlation with SMI was weak (r = 0.329). Conclusions: SMI assessment at L1 is achievable in patients with NSCLC receiving routine chest CT, with 96% having acceptable quality evaluations. Similar to results previously reported at L3, BMI showed poor correlation and low sensitivity to detect muscle mass loss. The use of CT at L1 is reliable and presents the opportunity for easier patient evaluation of sarcopenia in patients with lung cancer without the need for additional testing or radiation exposure.

KW - Cachexia

KW - Chest CT

KW - L1

KW - Lung cancer

KW - Sarcopenia

KW - Skeletal muscle mass

UR - http://www.scopus.com/inward/record.url?scp=85041553307&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85041553307&partnerID=8YFLogxK

U2 - 10.1007/s00520-018-4051-2

DO - 10.1007/s00520-018-4051-2

M3 - Article

SP - 1

EP - 7

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

ER -